Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyClover Health Imdelltra Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentClover HealthPolicy 6501-A

    Standard Medicare Part B Management Imdelltra

    Customize your policy alerts

    Sign up for clover_health Policy 6501-A alerts

    Get alerted when Policy 6501-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and authorization for Imdelltra (tarlatamab-dlle), including FDA-approved and compendial uses, for Clover Health members. It primarily covers extensive-stage small cell lung cancer after progression on or after platinum-based chemotherapy and sets initial and continuation authorization criteria.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Imdelltra
    Policy CodePolicy 6501-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for Imdelltra and document the applicable covered indication, treatment status, and clinical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial and continuation authorization duration
    ES-SCLCPrimary covered cancer indication
    Post-platinum progressionRequired disease setting
    Single agentInitial treatment configuration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5
    Compendia sources listed

    Coverage Criteria

    Initial therapy: extensive-stage small cell lung cancer

    Authorization for 12 months may be granted when all of the following criteria are met:

    Initial authorization

    • Disease and treatment setting

      • The member has extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
    • Regimen

      • Imdelltra (tarlatamab-dlle) is being used as a single agent.

    Continuation therapy

    Authorization for 12 months may be granted when all of the following criteria are met:

    Continuation authorization

    • Current treatment

      • The member is currently receiving therapy with the requested medication.
    • Covered indication

      • The requested medication is being used to treat an indication listed in the coverage criteria.
    • Benefit from therapy

      • Tolerability

        • There is no evidence of unacceptable toxicity while the member is on the current regimen.
      • Disease control

        • There is no evidence of disease progression while the member is on the current regimen.

    Other indications

    FDA-approved and compendial indications are covered when all approval criteria are met and the member has no exclusions to the prescribed therapy.

    • Approval criteria and exclusions

      • All applicable approval criteria are met, and the member has no exclusions to the prescribed therapy.
    • Individual assessment

      • For an indication other than the listed FDA-approved indication, the request is assessed on an individual basis.
    • Compendial support

      • The submission includes supporting evidence from Medicare-approved compendia.

        Required for indications other than the listed FDA-approved indication.

    Covered Regimens

    RegimenCovered indication
    Imdelltra (tarlatamab-dlle) as a single agentExtensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy

    Provider Actions

    Prior Authorization

    Obtain prior authorization for Imdelltra

    Prior authorization is required for Imdelltra. Initial authorization may be granted for 12 months for extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy when Imdelltra is used as a single agent; continuation authorization may also be granted for 12 months when continuation criteria are met.

    Documentation Required

    Submit compendial support for other indications

    For indications other than the listed FDA-approved indication, submit supporting evidence from Medicare-approved compendia with the authorization request.

    Background

    Imdelltra (tarlatamab-dlle) is covered for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. For this covered use, Imdelltra is authorized as a single agent. Other indications may be considered individually when supported by Medicare-approved compendia.

    Definitions

    Benefit from therapy
    TolerabilityNo evidence of unacceptable toxicity while on the current regimen.
    Disease controlNo evidence of disease progression while on the current regimen.
    Benefit requirementBoth tolerability and disease control must be present to demonstrate benefit from therapy.
    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Imdelltra
    Policy CodePolicy 6501-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for Imdelltra and document the applicable covered indication, treatment status, and clinical benefit.
    SourceLink
    On This Page
    Coverage CriteriaCovered RegimensProvider ActionsBackgroundDefinitions
    Denial Risk

    Meet the initial indication and regimen criteria

    Initial authorization may be denied if the member does not have extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy, or if Imdelltra is not being used as a single agent.

    Denial Risk

    Demonstrate benefit for continuation

    Continuation authorization may be denied if the member is not currently receiving Imdelltra, the medication is not being used for a covered indication, or the member is not benefiting from treatment. Benefit requires no evidence of unacceptable toxicity and no evidence of disease progression on the current regimen.

    Denial Risk

    Support unlisted indications with compendial evidence

    Indications other than the listed FDA-approved indication require individual assessment. Submit supporting evidence from Medicare-approved compendia with the request.